Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)

The modulating effects of the orally active epidermal growth factor receptor-specific tyrosine kinase inhibitor ZD 1839 (‘Iressa’) on cell growth and signalling were evaluated in four ovarian cancer cell lines (PE01, PE04, SKOV-3, OVCAR-5) that express the epidermal growth factor receptor, and in A2...

Descripción completa

Detalles Bibliográficos
Autores principales: Sewell, J M, Macleod, K G, Ritchie, A, Smyth, J F, Langdon, S P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375224/
https://www.ncbi.nlm.nih.gov/pubmed/11875715
http://dx.doi.org/10.1038/sj.bjc.6600058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375224/
https://www.ncbi.nlm.nih.gov/pubmed/11875715
http://dx.doi.org/10.1038/sj.bjc.6600058

Ejemplares similares